TP53BP1 and breast carcinoma: We also noted that USP50 siRNA treatment of the human breast cancer cell line MCF7 also increased 53BP1 foci numbers (Supplementary Fig. 3N), as did the treatment of mouse NIH3T3 cells with siRNA targeting murine USP50 (Supplementary Fig. 3N).